|
|
 |
|
Viewing report
|
|
|
|
SADC Pharmaceutical Industry
Frost & Sullivan, Nov 2010, Pages: 114
This study covers the pharmaceutical industry in key SADC countries, including Malawi, Mauritius and Zambia. The research service provides detailed metrics on the pharmaceutical industries, encompassing the OTC and prescription markets, as well as the branded and generic markets. The research examines drivers and restraints for growth, distribution, and geographical trends. Following from these, market growth are forecasted. In addition, an in-depth analysis of the competitive situation including vendors’ competitive rankings is provided. The base year is 2009 with forecasts running through 2016. The market is further divided into four subsegments including oncology, anti-diabetic drugs, anti-infective drugs and cardiovascular drugs.
This research service titled SADC Pharmaceutical Industry provides an analysis of four therapeutic segments in Mauritius, Zambia and Malawi. In this research, Frost & Sullivan's expert analysts thoroughly examine the following markets: anti-infective, oncology, diabetes and cardiovascular.
Market Overview
Improved Access to Pharmaceuticals Critical to Tackling the Increase in Infectious and Non-communicable Diseases
Infectious diseases in the Southern African Development Community (SADC) countries still present the biggest burden of disease. However, urbanisation and westernised lifestyles have led to the rise of non-communicable diseases, especially in countries like Mauritius, where they account for a majority of the country’s disease burden. Increased access to high-quality treatments is essential in alleviating the heavy burden of non-communicable diseases within the country. “The rapidly increasing number of diseases in SADC is the biggest driver of growth in the region,” notes the analyst of this research. “Infectious diseases, including AIDS, malaria and TB still present the largest opportunity for the provision of pharmaceuticals in the region, especially in Zambia and Malawi.” The high burden of infectious diseases will spur strong investments in anti-infective treatments. At the same time, the large number of non-communicable or lifestyle diseases like hypertension and diabetes will also drive market development.
“Rapid industrialisation and the consequent change to a more westernised lifestyle has contributed to the high prevalence of non-communicable disease risk factors in Mauritius,” remarks the analyst. “These include obesity (10.3%), abusive alcohol consumption (19.1%) and tobacco consumption (35.9% among males).” Non-communicable diseases such as cardiovascular disease and diabetes are the most common diseases in both hospital and non-hospital settings. They account for over 80.0 per cent of Mauritius’s disease burden. Mauritius ranks among the countries with the highest prevalence of diabetes mellitus and hypertension in Africa.
Limited buying power, an acute shortage of skilled healthcare workers and poor distribution infrastructure to rural areas still limit the access to essential treatments. Furthermore, the proliferation of low-quality and counterfeit products remains a major challenge for reputable pharmaceutical suppliers, as these products pose direct competition to high-quality pharmaceuticals. “Increased access to high quality treatments is essential in alleviating the high burden of non-communicable diseases,” advises the analyst. “Recently, the Ministry of Health in Mauritius has devoted more attention to the threat of non-communicable disease, realising that the high disease burden not only impacts healthcare services but also has a profound social and economic impact on the country.”
Market Sectors
Expert Frost & Sullivan analysts thoroughly examine the following market sectors in this research:
- Anti-infectives
- Oncology
- Diabetes
- Cardiovascular
By Country:
- Zambia
- Malawi
- Mauritius
Product samples
A sample for this product is available. Please Login/Register to download this sample.
|
|
|
|
